Karimah Es Sabar Sells 7,529 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 7,529 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director owned 7,529 shares of the company’s stock, valued at $240,928. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05.
• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.17, for a total value of $1,848,365.05.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $32.11 on Friday. Capricor Therapeutics, Inc. has a one year low of $4.30 and a one year high of $40.37. The stock has a 50-day moving average price of $27.38 and a 200 day moving average price of $19.10. The company has a market capitalization of $1.85 billion, a P/E ratio of -14.21 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities research analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus.
• Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
• Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
• Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
• Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
• Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the third quarter valued at $28,000. Parkside Financial Bank & Trust bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $36,000. Russell Investments Group Ltd. lifted its position in shares of Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares during the last quarter. ACT Capital Management LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $43,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $59,000. 21.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CAPR shares. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, March 10th. UBS Group set a $50.00 target price on shares of Capricor Therapeutics in a research report on Monday, December 15th. Oppenheimer upped their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Finally, Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.